Cargando…

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis

Here, we used MCF7 cells as a model system to interrogate how MYC/RAS co-operativity contributes to metabolic flux and stemness in breast cancer cells. We compared the behavior of isogenic MCF7 cell lines transduced with c-Myc or H-Ras (G12V), either individually or in combination. Cancer stem cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozsvari, Bela, Sotgia, Federica, Lisanti, Michael P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680558/ https://www.ncbi.nlm.nih.gov/pubmed/29080556 http://dx.doi.org/10.18632/aging.101304

Ejemplares similares

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito‐stemness and ribo‐stemness features
por: Peiris‐Pagès, Maria, et al.
Publicado: (2019)

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2018)

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells
por: De Luca, Arianna, et al.
Publicado: (2015)

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds
por: Ózsvári, Béla, et al.
Publicado: (2020)

High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy
por: Fiorillo, Marco, et al.
Publicado: (2021)

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy
por: Ozsvari, Bela, et al.
Publicado: (2017)

Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2017)

Azithromycin and Roxithromycin define a new family of “senolytic” drugs that target senescent human fibroblasts
por: Ozsvari, Bela, et al.
Publicado: (2018)

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
por: Sotgia, Federica, et al.
Publicado: (2018)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2019)

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
por: Ozsvari, Bela, et al.
Publicado: (2017)

A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
por: Ózsvári, Béla, et al.
Publicado: (2020)

Novel Metabolic Approaches Targeting Cancer Cells
por: Sebestyén, Anna, et al.
Publicado: (2023)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
por: Bonuccelli, Gloria, et al.
Publicado: (2016)

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
por: Lamb, Rebecca, et al.
Publicado: (2015)

Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
por: Bonuccelli, Gloria, et al.
Publicado: (2018)

Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production
por: Fiorillo, Marco, et al.
Publicado: (2020)

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells
por: Lamb, Rebecca, et al.
Publicado: (2015)

Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4
por: Martinez-Outschoorn, Ubaldo E, et al.
Publicado: (2013)

Molecular Analysis of Oncogenes, ras Family Genes (N‐ras, K‐ras, H‐ras), myc Family Genes (c‐myc, N‐myc) and mdm2 in Natural Killer Cell Neoplasms
por: Sugimoto, Kei‐ji, et al.
Publicado: (2002)

Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling
por: Peiris-Pagès, Maria, et al.
Publicado: (2018)

Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine
por: Sotgia, Federica, et al.
Publicado: (2017)

Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”
por: Fiorillo, Marco, et al.
Publicado: (2015)

Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy
por: Sotgia, Federica, et al.
Publicado: (2017)

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase
por: Fiorillo, Marco, et al.
Publicado: (2021)

Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability.
por: Arends, M. J., et al.
Publicado: (1993)

Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity
por: Sánchez-Alvarez, Rosa, et al.
Publicado: (2020)

High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant
por: Farnie, Gillian, et al.
Publicado: (2015)

Ras oncogene mutation in multiple myeloma
Publicado: (1989)

Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
por: Fiorillo, Marco, et al.
Publicado: (2017)

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy
por: Fiorillo, Marco, et al.
Publicado: (2018)

Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction
por: Lamb, Rebecca, et al.
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
por: Fiorillo, Marco, et al.
Publicado: (2019)

Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
por: Demma, Mark J., et al.
Publicado: (2019)

Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas
por: Tran, Phuoc T., et al.
Publicado: (2008)

K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc
por: Magudia, Kirti, et al.
Publicado: (2012)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5n67imoe8oql9eqecpknk91vep